ROCK1 and metabolic syndrome: Interestingly, therapeutic agents metformin and paeoniflorin target hepatic ROCK1/AMPK signaling to improve steatosis and dyslipidemia in DIO mice (14) and palmitate treated HepG2 cells, respectively (21).